Childhood Vaccinations — Schedule and Complications

• Antigen recognition and innate immune activation: Vaccines contain pathogen-associated molecular patterns (PAMPs) or adjuvants that activate pattern recognition receptors (PRRs) on dendritic cells and macrophages, triggering the innate immune response. Live attenuated vaccines (LAV) directly infect antigen-presenting cells (APCs) in respiratory or gastrointestinal mucosa, producing robust innate signals. Inactivated vaccines require adjuvants (aluminum salts, AS01B in Shingrix, MF59 in Fluzone High-Dose) to provide costimulatory signals via toll-like receptors (TLRs) and other PRRs. This innate activation is critical for subsequent adaptive immune response development and is the molecular basis for adverse local and systemic inflammatory reactions.

• Adaptive immune response generation—T cell and B cell priming: Antigen presentation by APCs to naïve CD4+ and CD8+ T cells in lymph nodes initiates the adaptive response. Helper T cells (Th1, Th2, Th17) differentiate based on cytokine milieu and antigen type. Th1 responses predominate with inactivated vaccines (IgG predominance), while LAV often generates balanced Th1/Th2 responses. B cells undergo germinal center reactions, producing plasma cells that secrete vaccine-specific antibodies and memory B cells that persist for years or decades. The immunoglobulin class shifts from IgM (primary response) to IgG (secondary response). Antibody affinity maturation occurs through somatic hypermutation and selection of high-affinity variants. For some vaccines (e.g., pertussis), antibody responses are critical; for others (e.g., varicella), both cell-mediated and humoral immunity provide protection.

• Memory immune response and durability: Following vaccination, long-lived plasma cells reside in bone marrow niches and continuously secrete antibodies, maintaining serum levels for months to years. Memory B cells and memory T cells persist in lymphoid tissues and circulation. Upon re-exposure to the same antigen (either through natural infection or booster vaccination), memory cells rapidly expand and differentiate into effector cells and new plasma cells, generating a secondary immune response that is faster, larger in magnitude, and produces higher-affinity antibodies than the primary response. This immunological memory is the basis for vaccine effectiveness and explains why booster doses enhance and prolong protection.

• Mechanism of adverse events: Local reactions (erythema, induration, pain) result from inflammatory responses to vaccine antigens and adjuvants at the injection site, mediated by innate immune cells and complement activation. Systemic reactions (fever, myalgia, malaise) reflect cytokine release (IL-1, IL-6, TNF-α, IFN-γ) during the innate and adaptive immune response. Fever commonly occurs 6-12 hours after inactivated vaccines and 7-14 days after LAV, representing physiological thermoregulation triggered by cytokines acting on the hypothalamic set point. Most adverse reactions are mild and self-limited. Severe reactions such as anaphylaxis result from IgE-mediated mast cell and basophil degranulation triggered by vaccine components (most commonly gelatin, egg protein in influenza and yellow fever vaccines, or latex from vial stoppers). Guillain-Barré syndrome (GBS) after certain vaccines (notably 1976 swine flu vaccine; rarely with current influenza vaccines) involves molecular mimicry between vaccine antigens and gangliosides on peripheral nerves, triggering autoimmune demyelination.

• Live attenuated vaccine-specific considerations: LAV strains replicate in host cells to levels sufficient to stimulate immune responses but are attenuated to prevent disease. This replication generates robust cellular and mucosal immunity (IgA antibodies). Viral shedding occurs and may rarely transmit to unvaccinated contacts. Immunocompromised individuals cannot be given LAV because attenuated virus may revert to virulent phenotype. Congenital infection is a theoretical concern for live vaccines given during pregnancy; therefore, LAV is contraindicated in pregnancy and women should avoid pregnancy for 28 days after receiving LAV (e.g., MMR, varicella).

• Age-based immunological capacity: Infants <6 weeks have maternal antibodies that passively block vaccine antigen presentation and impair response; vaccination timing accounts for waning maternal immunity. At 2 months of age, infants develop sufficient CD4+ T cell responses and germinal center formation. By 12-15 months, children mount robust IgG responses. Primary series spacing (typically 4-8 weeks between doses) optimizes immune priming without interference. Booster doses given 6-12 months after primary series achieve higher antibody titers than additional primary doses (demonstrates immunological memory).

• Immunocompromise as contraindication to LAV: Severe immunodeficiency (absolute CD4+ count <200 in HIV; hematologic malignancy; solid organ/stem cell transplant; chronic immunosuppressive therapy including TNF-α inhibitors) prevents adequate immune response to any vaccine and risks vaccine-strain disease from LAV. Mild immunocompromise (e.g., localized eczema, well-controlled asthma, topical corticosteroids, isolated IgA deficiency) does not contraindicate vaccination. Timing of vaccination relative to immunosuppressive therapies is critical: live vaccines should be given ≥4 weeks before immunosuppression begins or ≥3-4 weeks after live vaccine if immunosuppression will be delayed; inactivated vaccines may be given during immunosuppression but response may be suboptimal.

• Allergy history as risk factor for anaphylaxis: Prior anaphylaxis to vaccine components (egg protein, gelatin, neomycin, streptomycin, polymyxin B, yeast) or to PEG (polyethylene glycol, found in mRNA COVID-19 vaccines) mandates careful selection or avoidance of specific vaccines. Children with egg allergy can receive influenza vaccine (minimal residual egg protein) and MMR (prepared in cell culture, not eggs), but yellow fever vaccine should be avoided or administered under medical supervision. Latex allergy contraindicates vaccines with latex-containing stoppers; latex-free formulations are available.

• Seizure disorder and pertussis vaccine considerations: Uncontrolled seizure disorder or progressive neurological disease warrants deferral of pertussis-containing vaccines (DTaP, Tdap) because pertussis vaccine components (especially whole-cell pertussis in older formulations, now replaced by acellular pertussis [aP] in most countries) carry small risk of febrile seizures. Febrile seizure risk increases 2-14 days post-vaccination (incidence ~1 per 1,000-3,000 vaccine doses, mostly self-limited). Well-controlled seizure disorder is not a contraindication to pertussis vaccination because benefits outweigh risks. Family history of seizures or SIDS does not contraindicate vaccination.

• Timing of vaccination relative to other medications: Certain medications interfere with vaccine response or increase adverse event risk. Antibody-containing products (immune globulin, blood transfusions) contain passively transferred antibodies that may neutralize live vaccine virus; LAV should be deferred ≥3-11 months depending on product (higher antibody concentrations require longer deferral). Inactivated vaccines are unaffected by passive antibodies. Live vaccine spacing rule: if two LAV are not given simultaneously (same visit), they must be separated by ≥4 weeks to prevent viral interference. Antivirals (acyclovir, valacyclovir) given for herpes simplex or varicella treatment/prophylaxis inhibit replication of varicella LAV and should be discontinued ≥48 hours before vaccination; antivirals may be resumed ≥2 weeks after varicella vaccination.

• Recent infection as temporary contraindication: Acute febrile illness (especially with fever >38.5°C [101.3°F]) warrants deferral of vaccination to distinguish vaccine adverse events from illness effects and to optimize immune response (cytokine milieu may be altered during acute infection). Minor illnesses (upper respiratory infection, low-grade fever <38.5°C, otitis media, mild gastroenteritis) do not require deferral. Recovery from critical illness typically allows vaccination within 1-2 weeks.

Expected local reactions (occur in 25-75% of vaccinated children)

• Pain, erythema, and induration at injection site: Result from inflammatory infiltration of leukocytes (neutrophils, macrophages, T cells) responding to vaccine antigens and adjuvants. Typically develop within hours, peak at 24-48 hours, and resolve within 3-5 days. Swelling may extend 10-15 cm from injection site. These reactions are worse after booster doses than primary series because of enhanced memory immune response.
• Warmth and localized lymphadenopathy: Lymph nodes draining the injection site enlarge due to B and T cell proliferation; ipsilateral axillary nodes are affected after arm injections. Nodes are mobile, non-tender, <3 cm, and regress within 2-4 weeks.

Expected systemic reactions (occur in 5-30% depending on vaccine type)

• Fever: Peaks 6-12 hours after inactivated vaccines; 7-14 days after LAV (especially MMR and varicella). Fever exceeding 39°C (102.2°F) is uncommon with inactivated vaccines but occurs in 5-15% after MMR. Fever is physiological and indicates appropriate immune activation; antipyretic use (acetaminophen, ibuprofen) does not impair antibody response.
• Myalgia, malaise, and fatigue: Result from systemic inflammatory cytokines; more common in adults than young children. Symptoms peak at 24-48 hours and resolve within 1-3 days.
• Fussiness and irritability in infants: Behavioral changes occur after many vaccines, particularly pertussis-containing and pneumococcal vaccines. Maximal at 6-8 hours post-vaccination and resolve within 24 hours.

Vaccine-specific expected reactions

• Varicella vaccine: 3-5% develop varicella-like rash (typically 5-26 lesions, mild, centrally distributed) at 7-21 days post-vaccination due to LAV replication in skin. Rash poses minimal transmission risk (contacts should avoid the rash but varicella vaccine virus is rarely transmitted). Rash resolves within 2-4 weeks without scarring.
• Rotavirus vaccine: Mild diarrhea and vomiting occur in 1-3% within first week; inconsequential and doesn't affect immunity.
• MMR vaccine: Rash occurs in ~5% at 7-14 days (non-contiguous distribution distinguishes from vaccine strain), as do mild parotitis and lymphadenopathy. Pleurisy with transient chest discomfort has been reported in adolescents.
• Influenza vaccines: Myalgia disproportionately affects adults; local reactions more common than systemic reactions.

Serious and uncommon adverse events (present as medical emergencies)

• Anaphylaxis: Occurs within minutes to 30 minutes of vaccination (median 5 minutes). Characterized by urticaria, angioedema, bronchospasm, hypotension, and shock. Incidence is ~1-2 per million vaccine doses. Most common triggers are egg protein (influenza, yellow fever vaccines), gelatin, or neomycin. Presents with sudden onset of flushing, pruritus, urticaria, throat tightness, stridor, wheezing, nausea, vomiting, abdominal cramping, or syncope. Distinguishing from vasovagal syncope (which may occur with needle anxiety) is critical: anaphylaxis involves urticaria, bronchospasm, and hypotension; syncope involves vagal bradycardia and brief loss of consciousness without bronchospasm.

• Guillain-Barré Syndrome (GBS): Rare demyelinating peripheral neuropathy with reported association with certain vaccines, most robustly documented with 1976 swine influenza vaccine (risk ~1 per 100,000 vaccine doses, exceeding baseline incidence by 5-10 fold). Current influenza vaccines have minimal excess GBS risk (estimated 1-2 per million doses, risk often comparable to background incidence). Presents 1-3 weeks post-vaccination with ascending symmetric paralysis, areflexia, and demyelinating changes on nerve conduction studies. Presents as progressive weakness beginning in legs, ascending to involve trunk and arms; respiratory insufficiency may require mechanical ventilation. CSF shows albumin-cytologic dissociation (elevated protein without cell pleocytosis). EMG shows demyelination.

• Myocarditis/pericarditis: Rare myocardial inflammation reported with mRNA COVID-19 vaccines, particularly after second dose in adolescents and young adults. Risk ~5-70 cases per million vaccine doses (substantially lower than myocarditis risk from actual COVID-19 infection or other viral infections). Presents 2-7 days post-vaccination with chest pain, dyspnea, palpitations. Troponin elevation and ST elevation on ECG may mimic myocardial infarction. Most cases are mild and self-limited.

• Vaccine-strain disease from live attenuated vaccine: Extremely rare in immunocompetent recipients; occurs when attenuated vaccine strain reverts to virulence or replicates excessively in immunocompromised individuals inadvertently given LAV. Rotavirus vaccine transmitted from vaccinated infants to unvaccinated contacts has been reported but causes no illness. Vaccine-strain measles has occurred post-MMR in profoundly immunocompromised patients, presenting with typical measles manifestations 1-3 months post-vaccination.

Clinical evaluation

• Temporal relationship: Most acute vaccine adverse events occur within minutes to hours (anaphylaxis, syncope) or within 2-4 weeks (fever, rash, neurological symptoms). Establishing precise timeline of symptom onset relative to vaccination date is essential. Adverse events beyond reasonable biological plausibility warrant consideration of alternative diagnoses.
• Detailed allergy and immunization history: Document all prior vaccinations and any preceding adverse events (local vs systemic, severity, resolution timeline). Inquire about allergies to vaccine components (egg, gelatin, neomycin, PEG), antibiotics, latex. Family history of immunodeficiency or seizure disorders informs risk assessment.
• Physical examination: Assess injection site for size, extent, warmth, fluctuance (rule out abscess formation, typically bacterial superinfection from Staphylococcus aureus or Streptococcus pyogenes). Examine rashes carefully for distribution, morphology, and blanching quality (vaccine rashes are typically erythematous, maculopapular, non-blanching or minimally blanching, and follow dermatomal or localized distributions). Neurological examination for GBS includes assessment of strength (proximal > distal initially), reflexes (areflexia is hallmark), and cranial nerves (facial weakness common). Auscultation for wheezing, stridor, or pulmonary crackles.

Laboratory and diagnostic testing

• Anaphylaxis diagnosis (clinical diagnosis, not dependent on labs): Confirmed by clinical presentation alone; serum tryptase (mast cell degranulation marker) drawn within 15-30 minutes of symptom

Immediate stabilization — suspected anaphylaxis (minutes after injection)

• Epinephrine (alpha-1/beta agonist): first-line and the only drug that reverses the mechanism (mast-cell mediator–induced vasodilation, capillary leak, bronchospasm). Give 0.01 mg/kg of 1 mg/mL IM into the anterolateral thigh, maximum 0.3 mg in children (0.5 mg in adolescents/adults), repeated every 5–15 minutes as needed. Every vaccinating site should stock epinephrine per ACIP/CDC General Best Practice Guidelines for Immunization. Do not delay for antihistamines.
• Adjuncts, never substitutes: supine positioning with legs elevated, high-flow oxygen, isotonic crystalloid boluses for refractory hypotension, inhaled beta-2 agonist (albuterol) for bronchospasm, H1 antihistamine for urticaria/pruritus, and glucocorticoids only as an adjunct. AAAAI/ACAAI practice parameters note steroids do not reliably prevent biphasic reactions.
• Disposition: observe for a biphasic reaction — there is no universally agreed cutoff, but AAAAI/ACAAI guidance supports roughly 4 hours or more after symptoms resolve, with longer monitoring for severe or hypotensive reactions, patients requiring more than one epinephrine dose, and those with reactive airway disease. Discharge with an epinephrine autoinjector prescription and allergy/immunology referral for component testing (gelatin, egg, neomycin, PEG, latex).

Expected reactions

• Antipyretics/analgesics (acetaminophen or ibuprofen) and cool compresses for fever, injection-site pain, and fussiness. AAP does not endorse prophylactic antipyretics before vaccination because they may blunt antibody titers.

Serious events

• Guillain–Barré syndrome: IVIG or plasmapheresis with serial vital capacity/negative inspiratory force monitoring; corticosteroids are ineffective. Airway compromise is an ICU emergency.
• Post-mRNA myocarditis: supportive care, NSAIDs, exercise restriction per AHA/ACC myocarditis guidance; most cases resolve.

Contraindicated

• Live attenuated vaccines in severe immunocompromise and pregnancy; rotavirus in SCID or history of intussusception; any vaccine after prior anaphylaxis to that vaccine or a component; pertussis-containing vaccines after encephalopathy within 7 days of a prior dose (give DT/Td instead).

Emergencies

• Anaphylaxis: IgE-mediated degranulation against gelatin, egg, neomycin, PEG, or latex. Signalled by urticaria plus bronchospasm or hypotension within minutes; tryptase may rise but the diagnosis is clinical. Immediate IM epinephrine.
• Intussusception after rotavirus vaccine: a small excess risk, thought to reflect lymphoid hyperplasia creating a lead point, clustering in the first week after dose 1. Signalled by sudden colicky pain with legs drawn up, currant-jelly stool, and a target sign on ultrasound. Management is urgent air/contrast enema reduction unless there is perforation, peritonitis, or shock, which mandate surgical reduction.
• Guillain–Barré syndrome: molecular mimicry between vaccine antigen and peripheral nerve gangliosides. Ascending symmetric weakness with areflexia, albuminocytologic dissociation in CSF, demyelination on NCS. Falling vital capacity means intubation, not observation.
• Disseminated vaccine-strain disease: live vaccine given to an unrecognized immunodeficient infant (SCID, DiGeorge, HIV with severe CD4 depletion) allows unchecked replication — vaccine-strain measles, varicella, or rotavirus infection weeks to months later.

Non-emergent but tested

• Febrile seizures: cytokine-driven fever lowers the seizure threshold in susceptible young children, with peak risk 7–12 days after MMR/MMRV (the interval of vaccine-induced fever). Risk is measurably higher with MMRV combination vaccine than with separate MMR + varicella for the first dose at 12–47 months, which is why ACIP prefers separate injections for dose 1.
• Immune thrombocytopenia after MMR: transient autoantibody-mediated platelet destruction weeks post-vaccination; petechiae and isolated low platelets, usually self-limited.
• Vasovagal syncope: adolescent-specific, seen after HPV, Tdap, and MenACWY; bradycardia and pallor without urticaria or wheeze — the key discriminator from anaphylaxis. Head injury from falls is the real hazard, hence the ACIP 15-minute seated observation.
• Apnea/bradycardia in preterm infants after the first immunization series in hospitalized very-low-birth-weight infants — monitor, do not defer routine vaccination.
• Injection-site abscess or SIRVA: bacterial superinfection or bursal/subacromial deposition from an overly high deltoid injection, presenting as fluctuance or persistent shoulder pain with restricted range of motion.
• Failure to vaccinate: measles with subsequent SSPE, and infant pertussis with lymphocytosis and apnea — the true complication of hesitancy.

• Live vaccines to memorize: MMR, varicella, rotavirus, live attenuated influenza (intranasal), and yellow fever. These are the ones withheld in severe immunocompromise and pregnancy; everything else on the ACIP childhood schedule is inactivated, subunit, conjugate, toxoid, or mRNA.
• Two live vaccines: same day or ≥4 weeks apart. Per ACIP, this rule applies to live injectable vaccines (MMR, varicella, MMRV, yellow fever) and intranasal LAIV — give them together at one visit or separate by a month, since interferon from the first blunts take of the second.
• Exception: oral live vaccines (rotavirus, oral typhoid) may be given at any interval before, after, or with other live vaccines. Inactivated vaccines have no spacing rule.
• Rotavirus is age-locked: ACIP requires the first dose by 14 weeks 6 days and the final dose by 8 months 0 days. A later presentation means the series is not started or not completed — not "caught up." Prior intussusception and SCID are the disqualifiers.
• MMRV for dose 1 at 12–47 months raises febrile seizure risk versus separate MMR and varicella — the single most-tested combination-vaccine trap.
• Single best next step for post-vaccine urticaria with wheeze or hypotension: IM epinephrine into the anterolateral thigh. Diphenhydramine is the classic wrong answer.
• The distractor list — none of these justify deferral: mild illness or low-grade fever, current antibiotic use, breastfeeding, prematurity (vaccinate by chronologic age; HepB timing is the exception for infants under 2000 g), family history of seizures or SIDS, and a household contact who is pregnant or immunocompromised (household contacts should be vaccinated, with the caveat that LAIV is avoided around severely immunocompromised contacts).
• Egg allergy is not a contraindication to influenza vaccine under current ACIP recommendations, and MMR is grown in chick embryo fibroblasts — severe egg allergy does not bar it. Yellow fever vaccine is the true egg-related caution.
• The one association examiners love: encephalopathy within 7 days of a pertussis-containing vaccine is a permanent contraindication to further pertussis antigen — switch to DT/Td. By contrast, fever ≥40.5°C, a hypotonic–hyporesponsive episode, or persistent inescapable crying within 48 hours are precautions, not absolute bars.
• Any clinically significant adverse event goes to VAERS, a passive, hypothesis-generating surveillance system — it cannot establish causation, and the MMR–autism link has been definitively refuted.